📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 16:45
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Gilada Finance Q1 PAT at ₹45.37 Lakhs; Proposes 3x Increase in Authorised Capital
Gilada Finance & Investments reported a 16.5% YoY decline in net profit to ₹45.37 lakhs for Q1 FY27, down from ₹54.37 lakhs in Q1 FY26. Total income also decreased slightly to ₹1.73 Cr from ₹1.90 Cr in the corresponding quarter last year. A key development is the board's proposal to triple the Authorised Share Capital from ₹10 Cr to ₹30 Cr, signaling potential future equity fundraising. The company also allotted a small batch of NCDs worth ₹19 lakhs and scheduled its 32nd AGM for September 11, 2026.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and initiated a formal process to significantly expand its authorized capital base.
Why it mattersFor a micro-cap NBFC with a market cap of only ₹18 Cr, tripling the authorized capital is a major structural step that suggests the management is preparing for a significant equity infusion to scale its lending operations.
Q1 Net Profit: ₹45.37 lakhsYoY Profit Change: -16.5%Proposed Authorised Capital: ₹30 CrNCD Allotment Value: ₹19 lakhsNCD vs Net Worth: ~0.73%
📅 Short termThe stock may see limited movement due to the slight dip in quarterly earnings, though the capital increase proposal might generate speculative interest.
📈 Long termThe expansion of the capital base is structurally positive if followed by efficient fund deployment, but the company remains a micro-cap with high concentration risks.
⚠ Risk flags
- YoY decline in net profit and total income
- Potential equity dilution following the authorized capital increase
- Micro-cap liquidity risk
Key Highlights
Net profit for Q1 FY27 stood at ₹45.37 lakhs compared to ₹54.37 lakhs in Q1 FY26.
Total income for the quarter was ₹172.91 lakhs, a decrease from ₹189.95 lakhs YoY.
Proposed a 200% increase in Authorised Share Capital from ₹10 Cr to ₹30 Cr.
Allotted 19 Non-Convertible Debentures (NCDs) of ₹1 lakh each, totaling ₹19 lakhs.
32nd Annual General Meeting (AGM) scheduled for September 11, 2026, via video conferencing.
👀 What to Watch
Investors should monitor the upcoming AGM for details on the proposed capital increase, as this often precedes a rights issue or preferential allotment. Watch for the company's ability to reverse the YoY decline in profitability in the next quarter.
Rs 10 Cr NCD Allotment and Q1 Results Board Meeting on Aug 10, 2026
Gilada Finance & Investments has scheduled a board meeting for August 10, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. A key agenda item is the allotment of Non-Convertible Debentures (NCDs) worth Rs 10 crore on a private placement basis. This fundraise is highly material, representing approximately 53% of the company's current market capitalization of Rs 19 crore and 143% of its TTM revenue. The board will also finalize the notice for the upcoming Annual General Meeting.
Confidence: HIGH
What changedThe company is initiating a significant debt fundraise of Rs 10 crore and preparing to report its first-quarter financial performance for the 2026-27 fiscal year.
Why it mattersFor a micro-cap NBFC with a Rs 19 crore market cap, a Rs 10 crore capital infusion is substantial. It provides the necessary liquidity to expand its lending book, though it will also increase the company's leverage and interest obligations.
NCD Issue Size: Rs 10.00 CrNCD vs Market Cap: ~52.6%NCD vs TTM Revenue: ~142.8%Board Meeting Date: August 10, 2026Market Capitalization: Rs 19 Cr
📅 Short termThe stock may see interest leading up to the August 10 meeting as investors anticipate both the Q1 results and details of the NCD allotment.
📈 Long termIf the Rs 10 crore is deployed efficiently into high-yield lending assets, it could significantly scale the company's small revenue base (Rs 7 Cr TTM).
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High leverage risk given the fundraise size relative to equity
- Execution risk in deploying capital in a competitive NBFC space
- Low stock liquidity due to small market capitalization
Key Highlights
Board meeting scheduled for August 10, 2026, to consider Q1 FY27 results.
Proposed allotment of Rs 10 crore in Non-Convertible Debentures (NCDs) via private placement.
NCD issue size of Rs 10 crore is equivalent to ~143% of the company's TTM revenue of Rs 7 crore.
Trading window for designated persons remains closed until August 12, 2026.
Meeting to be conducted via Video Conferencing/Other Audio-Visual Means.
👀 What to Watch
Watch for the Q1 earnings release on August 10 to assess interest margins and the specific coupon rate/tenure of the Rs 10 crore NCDs, which will dictate future borrowing costs.
